Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $33.43 up 5.49% from its previous closing price of $31.69. In other words, the price has increased by $5.49 from its previous closing price. On the day, 1.57 million shares were traded. RARE stock price reached its highest trading level at $33.57 during the session, while it also had its lowest trading level at $31.603.
Ratios:
For a deeper understanding of Ultragenyx Pharmaceutical Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.30 and its Current Ratio is at 2.45. In the meantime, Its Debt-to-Equity ratio is 5.84 whereas as Long-Term Debt/Eq ratio is at 5.34.
Goldman Upgraded its Neutral to Buy on June 06, 2024, whereas the target price for the stock was revised from $56 to $67.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 13 ’25 when Horn Howard sold 7,942 shares for $31.51 per share. The transaction valued at 250,252 led to the insider holds 98,227 shares of the business.
Huizenga Theodore Alan sold 64 shares of RARE for $1,867 on Sep 18 ’25. The SVP, Chief Accounting Officer now owns 50,242 shares after completing the transaction at $29.17 per share. On Sep 12 ’25, another insider, KARAH PARSCHAUER, who serves as the Officer of the company, bought 2,450 shares for $31.17 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3221703936 and an Enterprise Value of 3618242560. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.28 while its Price-to-Book (P/B) ratio in mrq is 21.25. Its current Enterprise Value per Revenue stands at 5.93 whereas that against EBITDA is -7.704.
Stock Price History:
The Beta on a monthly basis for RARE is 0.28, which has changed by -0.44178265 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $57.99, while it has fallen to a 52-week low of $25.81. The 50-Day Moving Average of the stock is 11.63%, while the 200-Day Moving Average is calculated to be -6.12%.
Shares Statistics:
For the past three months, RARE has traded an average of 1.83M shares per day and 1404750 over the past ten days. A total of 96.18M shares are outstanding, with a floating share count of 89.64M. Insiders hold about 6.99% of the company’s shares, while institutions hold 96.79% stake in the company. Shares short for RARE as of 1759190400 were 7654589 with a Short Ratio of 4.18, compared to 1756425600 on 8320958. Therefore, it implies a Short% of Shares Outstanding of 7654589 and a Short% of Float of 8.2200006.
Earnings Estimates
Ultragenyx Pharmaceutical Inc (RARE) is presently subject to a detailed evaluation by 12.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$1.11, with high estimates of -$0.8 and low estimates of -$1.54.
Analysts are recommending an EPS of between -$4.48 and -$5.66 for the fiscal current year, implying an average EPS of -$5.06. EPS for the following year is -$3.71, with 12.0 analysts recommending between -$1.06 and -$5.57.
Revenue Estimates
A total of 16 analysts believe the company’s revenue will be $166.96M this quarter.It ranges from a high estimate of $175M to a low estimate of $158M. As of. The current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $139.49MFor the next quarter, 16 analysts are estimating revenue of $183.42M. There is a high estimate of $193.92M for the next quarter, whereas the lowest estimate is $172.07M.
A total of 19 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $668.55M, while the lowest revenue estimate was $641.7M, resulting in an average revenue estimate of $657.78M. In the same quarter a year ago, actual revenue was $560.23MBased on 19 analysts’ estimates, the company’s revenue will be $806.22M in the next fiscal year. The high estimate is $1.03B and the low estimate is $673.2M.
